BridgeBio Pharma Total Liabilities 2018-2024 | BBIO

BridgeBio Pharma total liabilities for the quarter ending June 30, 2024 were $1.876B, a 1.22% increase year-over-year.

  • BridgeBio Pharma total liabilities for 2023 were $1.889B, a 1.23% increase from 2022.
  • BridgeBio Pharma total liabilities for 2022 were $1.866B, a 0.71% decline from 2021.
  • BridgeBio Pharma total liabilities for 2021 were $1.88B, a 214.7% increase from 2020.

BridgeBio Pharma Total Liabilities 2018-2024 | BBIO

  • BridgeBio Pharma total liabilities for 2023 were $1.889B, a 1.23% increase from 2022.
  • BridgeBio Pharma total liabilities for 2022 were $1.866B, a 0.71% decline from 2021.
  • BridgeBio Pharma total liabilities for 2021 were $1.88B, a 214.7% increase from 2020.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19.4B
Dr Reddy's Laboratories (RDY)$12.6B
Bausch Health Cos (BHC)$3.4B
Amphastar Pharmaceuticals (AMPH)$2.4B
Supernus Pharmaceuticals (SUPN)$2B
Taysha Gene Therapies (TSHA)$307M
Personalis (PSNL)$241M
Assembly Biosciences (ASMB)$106M
Grace Therapeutics (GRCE)$30M
Sol-Gel Technologies (SLGL)$16M
Evoke Pharma (EVOK)$5M
Teligent (TLGT)$0M